It was recently announced that clinical medicine, Melphalan/HDS, which was manufactured by Delcath Systems, Inc. (NADAQ:DCTH) has been accepted for oral presentation. The medicine in question was manufactured, with the specific purpose of treatment for Unresectable Metastatic Ocular Melanoma.
This entity is responsible for delivering medical mechanisms, which focus primarily on the treatment of metastatic liver cancers. The study itself on the medicine was performed at the Moffitt Cancer Centre, which is located in Tampa, Florida.
More details about the oral presentation
The presentation, in particular, will be done on behalf of the company, at the Regional Cancer Therapies 12th International Symposium. This will take place between February 18, to February 20. According to information released regarding the matter, the event will be located at the Ski And Summer Resort, located in Austin.
It was announced today by Delcath that the presentation, in particular, will revolve around the case study, which the organisation was working on. This case study is called, Percutaneous Hepatic Perfusion For Unresectable Metastatic Ocular Melanoma To The Liver: A Multi-Institutional Report Of Outcomes.
In additional to Florida, the company also received aid in the processing of the report, from the University of Southampton, which is located in the United Kingdoms.
More details about what the study involves
The company also released broad keynotes, which illustrated the focus of the study. From the information released to the public, it can be determined that the study revolves around the entities treatment results, upon the application of Melphalan / HDS.
This report details illustrations of the progression of the drug, which was first instituted for testing in 2008, and the report carries through to 2016. It was also revealed that the study was led by a professor Dr Alexandra Gangi, who is based at the Moffitt Cancer Centre.
This is Default Discalimer. Please update this from the Intrinio Plugin setting page